Dividends & Buybacks ·
Atossa declares one CVR per share entitling holders to up to $50M from rare disease voucher sale
ATOSAtossa Therapeutics, Inc.
On November 10, 2026, Atossa Therapeutics announced its third quarter financial results and declared a dividend of one contingent value right (CVR) for each share of common stock outstanding as of October 19, 2026. The CVRs entitle holders to 25% of the net proceeds from the sale or monetization of the first FDA priority review voucher awarded to Atossa, capped at $50 million in aggregate payments. No voucher has been awarded yet, and there is no assurance that any payment will be made under the agreement. The company also reported a third-quarter operating loss of $5.9 million and provided updates on its (Z)-endoxifen clinical pipeline, including anticipated FDA IND clearances for Duchenne Muscular Dystrophy and McCune-Albright Syndrome in early 2027. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies in oncology and rare diseases.